A Phase II Study of BMS-354825 in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

Bristol-Myers Squibb1 site in 1 country96 target enrollmentJanuary 2005

ConditionsChronic Myeloid Leukemia Leukemia, Lymphoblastic, Acute, Philadelphia-positive

InterventionsDasatinib

DrugsDasatinib

Overview

Phase: Phase 2
Intervention: Dasatinib
Conditions: Chronic Myeloid Leukemia
Sponsor: Bristol-Myers Squibb
Enrollment: 96
Locations: 1
Primary Endpoint: Major and overall hematologic response rates
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia with primary or acquired resistance to imatinib mesylate.

Registry

clinicaltrials.gov

Start Date

January 2005

End Date

December 2007

Last Updated

15 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Bristol-Myers Squibb

Eligibility Criteria

Inclusion Criteria

•Subjects with Philadelphia chromosome positive (Ph+) (BCR/ABL+) lymphoid blast phase chronic myeloid leukemia whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate.
•Subjects who are considered to have lymphoid blast phase CML if they meet at least one of the following criteria: \*30% lymphoid blasts in peripheral blood or bone marrow. \*Extramedullary infiltrates of leukemic cells (other than in spleen or liver) with peripheral blood lymphoid blast morphology.
•ECOG performance status score 0-
•Adequate hepatic function defined as: \*Total bilirubin less than or equal to 2.0 times the institutional upper limit of normal; \*alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 times the institutional upper limit of normal.
•Adequate renal function defined as: \*serum creatinine less than or equal to 1.5 times the institutional upper normal limit.
•Men and women, 18 years of age or older.
•Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IC/L or equivalent units of HCG) within 72 hours prior to the start of study medication.

Exclusion Criteria

•WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period of at least 1 month before and for at least 3 months after completion of the study medication.
•WOCBP using a prohibited contraceptive method (not applicable).
•Women who are pregnant or breastfeeding.
•Women with a positive pregnancy test on enrollment or prior to study drug administration.
•Men whose sexual partners are WOCBP, who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period and for at least 3 months after completion of study medication.
•Subjects who are eligible and willing to undergo transplantation during the screening period.
•A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy.
•Demential or altered mental status that would prohibit the understanding or rendering of informed consent.
•History of significant bleeding disorder unrelated to CML.
•Concurrent incurable malignancy other than CML.

Arms & Interventions

1

Intervention: Dasatinib

Outcomes

Primary Outcomes

Major and overall hematologic response rates

Time Frame: throughout the study

Secondary Outcomes

Durability of hematologic response and time to hematologic response (major and overall)(throughout the study)
Assess cytogenetic and molecular responses(throughout the study)
Measure minor hematologic response rate in the imatinib resistant group(throughout the study)
Explore the role of BCR-ABL mRNA expression and point mutations in the BCR-ABL gene(throughout the study)
Measure the heath-related QOL using FACT-G(throughout the study)
To assess safety and tolerability of dasatinib(throughout the study)
Population PK(first month)